Company Overview of Chimerix, Inc.
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals to address unmet medical needs in the United States. The company’s lead compounds include brincidofovir (CMX001), an oral nucleotide analog that is in Phase III clinical trial for the prevention of cytomegalovirus (CMV) in adult hematopoietic cell transplant recipients, as well as to treat adenovirus infection; and CMX157, a nucleotide analog for the treatment of HIV and hepatitis B virus infections. Its preclinical testing product includes CMX669 for the treatment of BK virus and CMV. The company’s proprietary lipid technology and chemical library is under discovery and preclinical stage of ...
2505 Meridian Parkway
Durham, NC 27713
Founded in 2000
Key Executives for Chimerix, Inc.
Chief Executive Officer, President, Chief Medical Officer and Director
Total Annual Compensation: $419.3K
Chief Commercial Officer
Total Annual Compensation: $333.6K
Chief Medical Officer
Total Annual Compensation: $128.5K
Chief Development Officer
Total Annual Compensation: $228.1K
Compensation as of Fiscal Year 2014.
Chimerix, Inc. Key Developments
Chimerix, Inc. Presents at Stifel Healthcare Conference 2015, Nov-17-2015 11:45 AM
Nov 11 15
Chimerix, Inc. Presents at Stifel Healthcare Conference 2015, Nov-17-2015 11:45 AM. Venue: The New York Palace Hotel, Hubbard Room, New York, New York, United States. Speakers: M. Michelle Berrey, Chief Executive Officer, President, Chief Medical Officer and Director, William Garrett Nichols, Chief Medical Officer.
Chimerix Mulls Acquisitions
Nov 6 15
Chimerix, Inc. (NasdaqGM:CMRX) has filed a shelf registration to issue securities. Chimerix intends to use the net proceeds from the sale of the securities for general corporate purposes, which may include clinical trial and other research and development expenses, capital expenditures, working capital and general and administrative expenses, and potential acquisitions of or investments in businesses, products and technologies that complement its business.
Chimerix, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
Nov 5 15
Chimerix, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported net loss of $32.4 million, or $0.70 per basic and diluted share, for the third quarter of 2015. During the same period in 2014, the company recorded a net loss of $17.0 million, or $0.47 per basic and diluted share. Revenues for the third quarter of 2015 increased to $2.3 million compared to $1.2 million for the same period in 2014, due to an increase in the third quarter of 2015 in reimbursable expenses associated with the company's ongoing development contract with BARDA. Loss from operations was $32.7 million for the third quarter of 2015, compared to a loss from operations of $16.9 million for the same period in 2014. The variance was primarily due to the increased research and development, and general and administrative expenses.
For the nine months, the company reported total revenues of $7.652 million against $2.884 million a year ago. Loss from operations was $80.027 million against $38.640 million a year ago. Net loss was $79.529 million or $1.84 per basic and diluted share against $39.065 million or $1.26 per basic and diluted share a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|